NASDAQ:CELG - Celgene Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$85.23 -0.46 (-0.54 %)
(As of 07/16/2018 04:00 PM ET)
Previous Close$85.69
Today's Range$84.53 - $86.04
52-Week Range$74.13 - $147.17
Volume4.85 million shs
Average Volume7.32 million shs
Market Capitalization$62.11 billion
P/E Ratio12.46
Dividend YieldN/A
Celgene logoCelgene Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapies for the treatment of cancer and inflammatory diseases worldwide. It offers REVLIMID, an oral immunomodulatory drug for multiple myeloma (MM), myelodysplastic syndromes (MDS), and mantle cell lymphoma; POMALYST/IMNOVID to treat multiple myeloma; OTEZLA, a small-molecule inhibitor of phosphodiesterase 4 for psoriatic arthritis and psoriasis; and ABRAXANE, a solvent-free chemotherapy product to treat breast, non-small cell lung, pancreatic, and gastric cancers. The company's products also include IDHIFA, a small molecule inhibitor of the isocitrate dehydrogenase 2 to treat acute myeloid leukemia (AML); VIDAZA, a pyrimidine nucleoside analog for intermediate-2 and high-risk MDS, chronic myelomonocytic leukemia, and AML; and THALOMID to treat patients with MM and erythema nodosum leprosum. Its clinical stage products comprise OTEZLA for use in treating various immune-inflammatory diseases; luspatercept for the treatment of patients with beta-thalassemia and MDS; CC-486 to treat MDS, AML, and solid tumors; LSD1 inhibitor to treat non-hodgkin lymphoma and solid tumors; CC-122 and CC-220 to treat hematological and solid tumor cancers, and inflammation and immunology diseases; CC-92480 to treat multiple myeloma; and durvalumab, an anti-PD-L1 antibody for multiple hematological cancers. The company has agreement with BeiGene, Ltd; Acceleron Pharma, Inc.; Agios Pharmaceuticals, Inc.; Sutro Biopharma, Inc.; bluebird bio, Inc.; FORMA Therapeutics Holdings, LLC; OncoMed Pharmaceuticals, Inc.; NantBioScience, Inc.; AstraZeneca PLC; Lycera Corp.; Juno Therapeutics, Inc.; Nurix Inc.; Vividion Therapeutics, Inc.; Jounce Therapeutics, Inc.; Prothena Corporation plc; Zymeworks Inc.; and Evotec AG. The company was founded in 1980 and is headquartered in Summit, New Jersey.

Receive CELG News and Ratings via Email

Sign-up to receive the latest news and ratings for CELG and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations


Debt-to-Equity Ratio3.92
Current Ratio2.53
Quick Ratio2.36


Trailing P/E Ratio12.46
Forward P/E Ratio11.17
P/E Growth0.54

Sales & Book Value

Annual Sales$13.00 billion
Price / Sales4.75
Cash Flow$7.5760 per share
Price / Cash11.25
Book Value$8.79 per share
Price / Book9.70


EPS (Most Recent Fiscal Year)$6.84
Net Income$2.94 billion
Net Margins20.73%
Return on Equity72.92%
Return on Assets17.48%


Outstanding Shares724,830,000
Market Cap$62,110.43

The Truth About Cryptocurrencies

Celgene (NASDAQ:CELG) Frequently Asked Questions

What is Celgene's stock symbol?

Celgene trades on the NASDAQ under the ticker symbol "CELG."

When did Celgene's stock split? How did Celgene's stock split work?

Shares of Celgene split on Thursday, June 26th 2014. The 2-1 split was announced on Thursday, June 19th 2014. The newly minted shares were distributed to shareholders after the market closes on Wednesday, June 25th 2014. An investor that had 100 shares of Celgene stock prior to the split would have 200 shares after the split.

How will Celgene's stock buyback program work?

Celgene announced that its Board of Directors has authorized a stock repurchase program on Thursday, May 24th 2018, which permits the company to repurchase $3,000,000,000.00 in outstanding shares, according to EventVestor. This repurchase authorization permits the company to purchase up to 5.4% of its stock through open market purchases. Stock repurchase programs are typically a sign that the company's board believes its shares are undervalued.

How were Celgene's earnings last quarter?

Celgene Co. (NASDAQ:CELG) issued its quarterly earnings results on Friday, May, 4th. The biopharmaceutical company reported $2.05 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.96 by $0.09. The biopharmaceutical company had revenue of $3.54 billion for the quarter, compared to analyst estimates of $3.47 billion. Celgene had a return on equity of 72.92% and a net margin of 20.73%. Celgene's revenue was up 19.4% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $1.68 EPS. View Celgene's Earnings History.

When is Celgene's next earnings date?

Celgene is scheduled to release their next quarterly earnings announcement on Thursday, July, 26th 2018. View Earnings Estimates for Celgene.

What guidance has Celgene issued on next quarter's earnings?

Celgene updated its FY18 earnings guidance on Friday, May, 4th. The company provided earnings per share guidance of $8.45 for the period, compared to the Thomson Reuters consensus estimate of $8.45. The company issued revenue guidance of $14.8 billion, compared to the consensus revenue estimate of $14.81 billion.

What price target have analysts set for CELG?

33 brokerages have issued 1 year price targets for Celgene's shares. Their forecasts range from $85.00 to $166.00. On average, they anticipate Celgene's share price to reach $123.5185 in the next twelve months. This suggests a possible upside of 44.9% from the stock's current price. View Analyst Ratings for Celgene.

What is the consensus analysts' recommendation for Celgene?

33 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Celgene in the last year. There are currently 1 sell rating, 12 hold ratings and 20 buy ratings for the stock, resulting in a consensus recommendation of "Buy."

What are Wall Street analysts saying about Celgene stock?

Here are some recent quotes from research analysts about Celgene stock:
  • 1. Cowen Inc analysts commented, "We will be hosting a conference call with neurologist to discuss and TD-9855. Theravance is evaluating 1/2 trial in patients with . Results are expected to be available this month." (7/10/2018)
  • 2. Mizuho analysts commented, "We note that the language of highly statistically significant" results for the primary endpoint was used again. BOTTOM LINE: This trial was largely expected to work (Ph 2 data was encouraging, and MEDALIST worked) … probably ~$1 of additional DCF value creation… relatively small indication. Good incremental win for CELG." (7/10/2018)
  • 3. Canaccord Genuity analysts commented, "We expect median Progression Free Survival (PFS) > 10 months for the initial bb2121 dose escalation cohort previously reported at ASH 2017, based on 71% progression free at 9 months. Importantly, we believe PFS data could easily exceed our estimate and the 8.8 months PFS seen for pomalidomide + daratumumab + dexamethasone in Phase 1b. Duration of follow-up key for new n=21 patient cohort Investors should carefully consider the median follow-up time for the new n=21 patient bb2121 cohort with no BCMA expression cutoff, since Complete Responses improve over time. We will consider the initial bb2121 data presented at AACR in 2016, where a 78% ORR and 22% CR rate was seen. Importantly, we expect a very rapid Overall Response Rate, as seen for initial bb2121 data." (5/30/2018)
  • 4. According to Zacks Investment Research, "Celgene’s first-quarter results were encouraging as the company beat on both sales and earnings. Revlimid sales were impressive yet again along with Pomalyst and Otezla. Celgene’s key growth driver, Revlimid, continues to drive revenues. However, a late stage study on Revlimid in combination with Rituxan failed. Celgene suffered yet another setback when it received Refusal to File letter from the FDA regarding its New Drug Application for multiple sclerosis candidate ozanimod. Celgene was on the look-out of new deals and acquisitions given a lacklustre 2017 and the Juno acquisition was on the same track. We are positive on the acquisition. The bluebird deal will further bolster Celgene’s presence in the CAR-T space. The company has a few data read-outs lined up for the rest of the year on key drugs. Shares have underperformed the industry in the last six months." (5/10/2018)
  • 5. Cann analysts commented, "Celgene announced today that John Weiland has been elected to its board of directors. Mr. Weiland was most recently President and Chief Operating Officer of C.R. Bard, Inc. Prior to this role, Mr. Weiland held the position of Group President of Bard and had global responsibility for Bard Medical Division, Bard Urological Division, Davol Inc., Bard Endoscopic Technologies Division and Bard’s Worldwide Manufacturing Operations. We believe Mr. Weiland will bring significant commercial and operational experience to the Celgene Board." (2/15/2018)

Are investors shorting Celgene?

Celgene saw a drop in short interest in June. As of June 29th, there was short interest totalling 15,381,014 shares, a drop of 35.8% from the June 15th total of 23,941,180 shares. Based on an average daily volume of 6,524,272 shares, the days-to-cover ratio is presently 2.4 days. Currently, 2.1% of the company's shares are short sold. View Celgene's Current Options Chain.

Who are some of Celgene's key competitors?

Who are Celgene's key executives?

Celgene's management team includes the folowing people:
  • Mr. Mark J. Alles, Chairman & CEO (Age 59)
  • Mr. Peter N. Kellogg, Exec. VP, CFO & Chief Accounting Officer (Age 62)
  • Dr. S. J. Rupert Vessey, EVP, Pres of Research & Early Devel. (Age 53)
  • Mr. Patrick E. Flanigan III, Corp. VP of Investor Relations
  • Mr. Gerald F. Masoudi, Exec. VP, Gen. Counsel & Corp. Sec. (Age 50)

Has Celgene been receiving favorable news coverage?

News articles about CELG stock have trended somewhat negative this week, according to Accern Sentiment Analysis. The research group scores the sentiment of press coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Celgene earned a coverage optimism score of -0.01 on Accern's scale. They also assigned media stories about the biopharmaceutical company an impact score of 45.76 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company's share price in the near future.

Who are Celgene's major shareholders?

Celgene's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Swedbank (0.54%), NN Investment Partners Holdings N.V. (0.25%), LGT Capital Partners LTD. (0.08%), Gateway Investment Advisers LLC (0.07%), Handelsbanken Fonder AB (0.07%) and Gofen & Glossberg LLC IL (0.06%). Company insiders that own Celgene stock include Corp /De/ Celgene, Ernest Mario, Gilla Kaplan, James J Loughlin, Mark J Alles, Michael A Friedman, Michael D Casey, Richard W Barker, Robert J Hugin, Rupert Vessey and Terrie Curran. View Institutional Ownership Trends for Celgene.

Which major investors are selling Celgene stock?

CELG stock was sold by a variety of institutional investors in the last quarter, including NN Investment Partners Holdings N.V., Capital One National Association, Webster Bank N. A., Community Bank & Trust Waco Texas, Fjarde AP Fonden Fourth Swedish National Pension Fund, Atria Investments LLC, Macguire Cheswick & Tuttle Investment Counsel LLC and Rathbone Brothers plc. Company insiders that have sold Celgene company stock in the last year include Ernest Mario, Gilla Kaplan, James J Loughlin, Michael D Casey and Terrie Curran. View Insider Buying and Selling for Celgene.

Which major investors are buying Celgene stock?

CELG stock was bought by a variety of institutional investors in the last quarter, including Swedbank, LGT Capital Partners LTD., Gateway Investment Advisers LLC, Gofen & Glossberg LLC IL, Welch & Forbes LLC, Neville Rodie & Shaw Inc., Addenda Capital Inc. and DnB Asset Management AS. Company insiders that have bought Celgene stock in the last two years include Corp /De/ Celgene and Mark J Alles. View Insider Buying and Selling for Celgene.

How do I buy shares of Celgene?

Shares of CELG can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Celgene's stock price today?

One share of CELG stock can currently be purchased for approximately $85.22.

How big of a company is Celgene?

Celgene has a market capitalization of $62.11 billion and generates $13.00 billion in revenue each year. The biopharmaceutical company earns $2.94 billion in net income (profit) each year or $6.84 on an earnings per share basis. Celgene employs 7,467 workers across the globe.

How can I contact Celgene?

Celgene's mailing address is 86 MORRIS AVENUE, SUMMIT NJ, 07901. The biopharmaceutical company can be reached via phone at 908-673-9000 or via email at [email protected]

MarketBeat Community Rating for Celgene (NASDAQ CELG)

Community Ranking:  3.8 out of 5 (star star star)
Outperform Votes:  1,794 (Vote Outperform)
Underperform Votes:  591 (Vote Underperform)
Total Votes:  2,385
MarketBeat's community ratings are surveys of what our community members think about Celgene and other stocks. Vote "Outperform" if you believe CELG will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CELG will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 7/16/2018 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.